Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001260436 | SCV001437433 | uncertain significance | not specified | 2022-05-31 | criteria provided, single submitter | clinical testing | Variant summary: CBL c.195+12_195+13delinsTT alters a nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 4/4 computational tools predict no significant impact on normal splicing, however, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00011 in 178174 control chromosomes (gnomAD), predominantly at a frequency of 0.0016 within the East Asian subpopulation in the gnomAD database, including 1 homozygote. To our knowledge, no occurrence of c.195+12_195+13delinsTT in individuals affected with Noonan Syndrome-Like Disorder and no experimental evidence demonstrating its impact on protein function have been reported. One ClinVar submitter has assessed the variant since 2014: the variant was classified as likely benign. Based on the evidence outlined above, the variant was classified as uncertain significance. |
Labcorp Genetics |
RCV002069377 | SCV002341731 | likely benign | RASopathy | 2024-01-14 | criteria provided, single submitter | clinical testing |